Summary Background We attempted to determine the maximum tolerated dose and toxicity of etoposide (VP-16) when administered in combination with carboplatin (CBDCA) (300 mg m-2) and administered via the intraperitoneal (IP) route.
Summary Background We attempted to determine the maximum tolerated dose and toxicity of etoposide when administered in combination with carboplatin (CBDCA) (300 mg m-2) and administered via the intraperitoneal (IP) route.
Methods and Materials A total of 26 patients were treated on this trial. CBDCA was administered at a fixed dose of 300 mg m-2) while VP-16 was started at a dose of 200 mg m2 and escalated at 50 mg m-2 increments. Both agents were mixed together in 2 litres of 5% Dextrose and administered as quickly as possible into the peritoneal cavity. Pharmacokinetic studies were performed at the maximum tolerated dose (MTD).
Results The MTD for this regimen was CBDCA 300 mg m-2 and VP-16 350 mg m-2. Patients > 70 years of age or who had received more than six cycles of previous chemotherapy, tolerated this regimen poorly. The MTD for this group of patients was CBDCA 200 mg m-2 and VP-16 50 mg m-2. Neutropenia was the dose limiting toxicity for both groups. The mean peritoneal/plasma peak ratio was 18.3 for CBDCA and 12.7 for VP-16. The pharmacologic advantage (peritoneal/plasma AUC ratio) was 14.9 for CBDCA and 8.8 for VP-16. Although measurable disease was not a requirement for entrance into this study a response rate of 27% was noted in 15 patients with evaluable disease who had ovarian cancer.
Conclusions A pharmacologic advantage exists for both CBDCA and VP-16 when administered together via the IP route.
We have recently completed phase I and II trials of the combination of high dose cisplatin and etoposide administered concurrently via the intraperitoneal route (Howell et al., 1990; Kirmani et al., 1988; Zimm et al., 1987) . This combination demonstrated substantial activity as both a salvage regimen as well as initial therapy (Howell et al., 1990; Kirmani et al., 1988) . This information has been used to design a phase III prospective randomised trial comparing standard intravenous cisplatin and cyclophosphamide with high dose cisplatin and etoposide administered intraperitoneally that is currently ongoing at the UCSD Cancer Center.
Carboplatin, a cisplatin analogue, has recently been approved for use for the treatment of ovarian cancer by the Food and Drug Administration. It has demonstrated substantially less nephrotoxicity, neurotoxicity and ototoxicity while it appears to be as effective as cisplatin for the treatment of ovarian cancer when used in appropriate doses (Alberts et al., 1985; Anderson et al., 1988; ten Bokkel Huinink et al., 1988) . Additionally two phase I and one phase II trials of the intraperitoneal administration of car- boplatin have been completed (DeGregorio et al., 1986; Elferink et al., 1988; Speyer et al., 1990 Patients were hospitalised for the initial course of therapy. Those patients who tolerated therapy well (minimum nausea and vomiting) were eligible for treatment as an outpatient. The appropriate dose of carboplatin and etoposide was mixed together in two litres of 5% dextrose in water and administered as rapidly as possible (45-90 min) into the peritoneal cavity. HPLC analysis demonstrated that the two drugs were chemically compatible and failed to react with each other at these concentrations (data not shown). A totally implanted peritoneal access system (Port-a-Cath, Pharmacia nuTech, Piscataway, New Jersey) was used in this study. Fluid was not removed from the peritoneal cavity. No systemic hydration was used routinely unless the patient encountered significant problems with nausea and vomiting. The anti-emetic regimen included the use of lorazepam, metaclopramide and diphenhydramine.
Sample collections and pharmacokinetics Blood samples were obtained prior to therapy and then at 14 additional time points over an 8 h interval from the start of chemotherapy. In addition, blood samples were collected at 8, 12, and 24 h. The peritoneal fluid samples were collected at the instant the IP infusion ended (ranging from 45-90 min) and every hour for 8 h after the start of chemotherapy. Additional samples were collected at 24 h.
The blood and peritoneal fluid samples were drawn into chilled heparinised tubes and then immediately centrifuged at 1000 g for O min at 4°C to remove the formed elements. A portion of the peritoneal and plasma fluid samples was immediately ultrafiltered by centrifugation through CF25A filter cones (Amicon Corp., Lexington, Massachusetts). The unfiltered plasma and peritoneal fluid samples, as well as their respective ultrafiltered samples, were frozen at -70°C for later carboplatin and etoposide analysis.
Ultrafilterable carboplatin concentrations were measured in the form of elemental platinum by graphite furnace atomic absorption spectroscopy using a Perkin-Elmer 373 atomic absorption spectrophotometer equipped with an HGA-2200 graphite furnace, with a lamp current of 15 mA and monitoring of the 265.9 nm line. Injection of volumes of 2 to 20 pl of thawed ultrafiltrate were analysed using the following temperature program: dry at 100°C for 50 s, ramp to 1300°C over 10 s, char at 1300°C for 15 s, and atomise at 2350°C for 7 s.
The standard lines for both peritoneal fluid and plasma samples were constructed by dissolving cisplatin (BristolMyers Company, Syracuse, New York) in 0.9% saline.
Total etoposide concentrations were determined by using reverse phase high performance liquid chromatography as previously described (Strife et al., 1986; Zimm et al., 1987 In order to model the pharmacokinetic data, account must be taken of the fact that drug instillation did not occur instantaneously but required 45-90 min. Thus one and two compartment models that consider only the decay are not entirely appropriate. In order to model the situation more accurately coupled differential equations were set up to model the elimination and exchange of carboplatin or etoposide (drug) between the peritoneal and plasma compartments by a method previously described (Goel et al., 1989; 1992) .
The pharmacokinetics of carboplatin during infusion (O < t < T) can be depicted by the system diagram (see Figure 1 ) where VI and V2 are the apparent volumes of the respective compartments, k12 and Ke, are the elimination rate constants and Q is the flow rate into the peritoneal cavity. Under the first order kinetics, differential equations describing the rates at which the concentrations in each compartment CI(t) (peritoneal cavity) and C2(t) (plasma) change with 
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After infusion (t , T), the system diagram is as shown in Figure 1 , and the differential equations are:
The solutions are: Where A' and A2 are intercepts determined for each of the compartments determined by extrapolation of the elimination phase of the curve to t = 0. Continuity requirements at t = T allow us to determine Al and A2. Thus equations (1) and (3) are combined -and similarly with equations (2) and (4) -to give:
k, -k12
where (r)+= max (O,T), for all t > 0.
An iterative one-dimensional 'grid search' for k,2, coupled with standard linear regression to estimate Q/V,, was used to fit Equation (5) to the peritoneal carboplatin measurements of each patient: least squares estimates of Q/V, and k12 were thus obtained. The estimate of k,2 was then inserted in equation (6) and held fixed, and by the same technique least squares estimates of Q/V2 and ke were obtained from the patient's plasma CBDCA measurements. The major pharmacokinetic parameters were then calculated.
The areas under the fitted concentration (AUCs) vs time curves were calculated by the integration of the corresponding peritoneal and plasma equations out to t = mo. The results were AUC = (Q/Vlkl2)T for the peritoneum and AUC = (Q/V2ke)T for the plasma. The volume of distribution is then given by dose/(kl2 * AUC) for the peritoneum and dose/(ke AUC) for the plasma. Clearance is given by dose/ AUC, and half-life is given by In 2/(elimination rate constant). The peritoneal mean residence time is given by (1/ k,2) + (T/2). Calculations were carried out on the data for each patient separately.
Results
Toxicity Ninety-two courses were administered to 26 patients. The major dose limiting toxicity encountered in this study was myelosuppression. Tables I and II present the hematologic toxicity as a function of dose for the high and low risk groups respectively. Grade 4 toxicity was seen in both neutrophil and platelet lineages and both qualified as dose limiting toxicity for both low and high risk groups. The recommended phase II dose is carboplatin 300mgm-2 and etoposide 100 mg m-2 for high risk patients and carboplatin 300mgm-2 and etoposide 350mgm-2 for low risk patients.
Only two of the courses were associated with neutropenic fever. Offending organisms were not identified and the patients recovered on appropriate antibiotic coverage. One patient had a culture documented infectious peritonitis that was successfully treated without having to remove the port- 
Pharmacokinetics
The pharmacokinetics of ultrafilterable carboplatin at a dose of 300 mg m-2 and total etoposide at a dose of 350 mg m 2 were each determined for six separate courses of therapy in six different low risk patients. Each patient had a creatinine clearance that was greater than 60 ml min-'. Figure 2 shows the plasma and peritoneal concentrations of carboplatin, measured as elemental ultrafilterable platinum; Figure 3 shows the concentrations of total etoposide. The pharmacokinetic parameters are summarised in Tables III and IV. As shown in Figure 2 , peritoneal concentrations of carboplatin were markedly higher than plasma concentrations. The total AUC of carboplatin in the peritoneal and plasma compartments were 3,673 ± 4,202 (SD) ,LM-h and 247 + 194 gM h respectively and the mean peritoneal:plasma AUC ratio (± standard deviation) was 14.5 ± 6.9.
As shown in Figure 3 peritoneal concentrations of total etoposide were also markedly higher than plasma concentrations. The total AUC in the peritoneal and plasma compartments were 2,752 ± 2,109 fg h ml-' and 314± 123 ig h ml' respectively. The mean AUC ratio was 9.6 ± 9.5. 0  1  2  3  4  0  1  2  3  4  100  50  1  1  1  0  0  0  0  1  0  0  0  0  200  50  10  16  5  1  6  4  0  8  2  3  2  1  300  50  9  18  0  5  7  2  4  3  2  5  4  4  300  100  4  4  0  2  0  0  2  1  0  0  2  1  300  150  1  1  0  0  0  1  0  0  0  0  1  0  300  200  1  1  0  1  0  0  0  0  1  0  0  0  Total  41 aHigh risk -more than six prior cycles of chemotherapy or age greater than 70. (Howell et al., 1990) . A further increase in dose intensity could be accomplished by increasing cisplatin dose, but the cisplatin dose cannot be increased above 270 mg m-2 even when thiosulfate is used, before encountering dose-limiting non-hematologic toxicities (Pfeifle et al., 1985) . In contrast, carboplatin has been given successfully at doses up to 1600 mg m-2 without substantial toxicity other than bone marrow suppression Shea et al., 1989) The dose achieved in low risk patients compares favourably with that achieved in several phase I-II studies using this combination administered systemically. Bishop et al. (1987) evaluated the efficacy and toxicity of carboplatin (100 mg m-2) and etoposide (120 mg m-2) administered intravenously daily for 3 days in 94 patients with previously untreated small cell lung cancer. According to the Common Toxicity Grading Scale, Grade 3 or 4 neutropenia and thrombocytopenia occurred in 63% and 20% of patients respectively. Two patients died of neutropenic septic shock.
Response
Smith et al. (1987) evaluated this combination using a slightly different dose and schedule in a similar patient population. Carboplatin was given at a dose of 300 mg m-2 intravenously on day 1 while etoposide was administered at a dose of 100 mg m-2 on days 1 through 3. Common Toxicity Scale grade 3 or 4 neutropenia and thrombocytopenia occurred in 43% and 10% of patients respectively. One patient died of neutropenic septic shock.
In the present study, two of five patients treated with carboplatin at a dose of 300 mg m-2 and etoposide at a dose of 400 mg m-2 experienced grade 4 hematologic toxicity. Thus carboplatin 300 mg m-2 and etoposide 350 mg m-2 was identified as the maximum tolerated dose.
As expected, the pharmacokinetic studies confirmed the significant pharmacologic advantage that can be achieved when these agents are administered via the intraperitoneal route. The peak concentration (mean ± SD) of carboplatin in the peritoneal cavity averaged 18.3 ± 7.6 (SD) fold higher than that in the plasma and the peritoneal/plasma AUC ratio averaged 14.5 ± 6.9. Also of importance is the fact that cytotoxic peritoneal concentrations were maintained for longer than 24 h; thus the practice of draining the abdomen after a 4 to 6 h dwell could result in a significant reduction in peritoneal drug exposure. Elferink et al. (1988) studied the pharmacokinetics of intraperitoneal carboplatin administered as a single agent at a dose of 300 mg m-2. The AUC ratio of 11.0 ± 8.0 that they determined was similar to our ratio of 14.5 ± 6.9. Strict comparison of other pharmacokinetic parameters could not be made as they used a two compartment model analysis. In Elferink's analysis, within each body cavity, a pharmacologic 2-compartment model is used while in our study, within each body cavity, a pharmacologic one-compartment model is used.
Similarly, DeGregorio et al. (1986) We also compared our etoposide data with that obtained in our previous pharmacokinetic study of cisplatin and etoposide administered intraperitoneally (Zimm et al., 1987) . The dose of etoposide evaluated was 350 mg m-2 in both studies. Due to differences in variances only the clearance and peak concentration in the peritoneal cavity could be compared (simultaneous F tests of the hypothesis of equal variances, data analysis not shown). The present study yields a longer half life (5.3 ± 1.4 h vs 3.1 ± 0.2 h) and a higher peak concentration (302.2 ± 27.3,ug ml' vs 189 ± 2.2 tLg ml-'). A similar problem of differences in variances limited comparison of plasma values to half life, AUC peak concentration and time of peak concentration. The present half life of 1.3 ± 0.4 was significantly shorter than the 5.8 ± 0.6 obtained in the previous study while no difference was noted in the AUC (314.5 ± 50.3 g-h ml' vs 356 ± 14 ggh ml-') peak concentration (27.67 ± 3.6 lg ml-' vs 32 ± 3.1 fig ml-') or time of peak concentration (3.3 ± 0.4 h vs 3.7 ± 0.2 h). The slow peritoneal clearance in the present study is consistent with the higher peak peritoneal concentration achieved, however, despite a significant decrease in plasma half life there was no affect on the AUC or peak concentration.
Recent data from Los et al. (1990) has called into question the rationale of using carboplation via the intraperitoneal route. Their data suggest that carboplatin is far less efficient than cisplatin in penetrating tumours. In fact, ten times more carboplatin was required to achieve tumour content of platinum equal to that of cisplatin in their rat model. Despite this information, in this trial, clinically meaningful responses were observed in patients with ovarian cancer. The overall response rate was 27% in ovarian cancer patients.
Similarly, Markman et al. (1992) have recently reported an overall response rate of 38% in patients with ovarian cancer treated with these same agents IP. In this study, 44% of patients with disease 0.5 cm responded with eight (32%) achieving a complete response. In our own study, three of the four patients with ovarian cancer that responded to this combination had previously received systemic cisplatin. One of the four patients had also received high doses of cisplatin (1200 mg m-2 total dose) administered intraperitoneally. This clinical response suggests activity of intraperitoneal carboplatin and etoposide in patients with ovarian cancer who have previously failed or relapsed from cisplatin containing regimens and argues strongly for continued evaluation of this combination in combination with colony stimulating factors to allow further dose escalation.
